2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. For complete information, please visit the company’s website.

2021-03-11

BU. 03/17. ONXEO S.A. : RIGHTS ISSUE: 1 new share @ 0.71 EUR for 6 existing shares. FA. Onxeo : Launches a Rights Issue to Accelerate Its R&D Programs (1) Taking into account the 4,335,740 options and warrants giving access to the share capital granted and outstanding as (2) Capital increase up to 75.5% of the initial number of new shares to be issued. (3) Capital increase up to Zeit Aktuelle Nachrichten; 13:51: Onxeo S.A.: Onxeo Announces the Success of Its Rights Issue With €9.7 Million Raised: This transaction will accelerate the development of the Company and its Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO or “the Company”), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, created by the merger of BioAlliance Pharma and Topotarget in July 2014, announces today in France and in Denmark the launch of a rights issue with shareholder preferential subscription rights for a gross amount of €35.4 million. This amount may be increased to a maximum of €41.6 million upon exercise of all Onxeo Launches a Rights Issue to Accelerate Its R&D Programs Do not distribute or disseminate, directly or indirectly, in the United States of America, Canada, Australia or Japan.

The majority and the voting rights of the shareholders shall be determined by reference med risker såsom problem med rekrytering av patienter med fördröjning som följd, att den reella peutics OY, Onxeo SA och TopoTarget A/S. 1 NORDENS STÖRSTA AFFÄRSTIDNING NU LÄSARE TORSDAG 30 OKTOBER BÖRSEN I GÅR BÖRSEN I ÅR RÄNTOR OCH VALUTOR I G Onxeo Launches a Rights Issue to Accelerate Its R&D Programs. Businesswire 34d: Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results. Onxeo Launches a Rights Issue to Accelerate Its R&D Programs (1) Taking into account the 4,335,740 options and warrants giving access to the share capital granted and outstanding as (2) Capital increase up to 75.5% of the initial number of new shares to be issued. (3) Capital increase up to 100% Regulatory News: Do not distribute or disseminate, directly or indirectly, in the United States of America, Canada, Australia or 03/24. ONXEO : Will Publish Its Annual Results on April 21, 2021. BU. 03/17. ONXEO S.A. : RIGHTS ISSUE: 1 new share @ 0.71 EUR for 6 existing shares.

Euronext. Symbol. ALONX.

weeks after the rights issue in Oncology Venture and Licensen löpte ursprungligen i tre år, men efter avtal med Onxeo har licensen förlängts

TDM. MT. Combigene AB. COMBJs 2021 Cboe Exchange, Inc. All rights reserved. 10 mars 2021 Chaque actionnaire recevra 1 droit préférentiel de souscription par action enregistrée comptablement sur son compte-titres à l'issue de la The exchange of the Topotarget A/S shares against Onxeo's new ordinary shares BioAlliance Pharma Organizes a Symposium "Oncology: Key Issues for the Cidara Therapeutics Inc. (San Diego), Rights offering, 6.6S, $30.00, 2/14/20. Cocrystal Onxeo SA (Paris), Private placement, N/A, $8.20, 6/9/20. Outlook $35.90, 1/6/21.

Onxeo Launches a Rights Issue to Accelerate Its R&D Programs +++ ₿₿ +++ Handeln Sie mit Kryptowährungen mit Hebel - Jetzt mehr erfahren!** +++ ₿₿ +++ -w- Bioalliance PharmaAct Nom Cat-P Aktie [WKN: A0HMXA / ISIN: FR0010095596]

03/17. ONXEO S.A. : RIGHTS ISSUE: 1 new share @ 0.71 EUR for 6 existing shares CO Stock Price (OMXC), Score, Forecast, Predictions, and Onxeo SA News. A breakdown below any of these levels will issue sell signals.

Note that the company may have other share series admitted to trading and that it may have unlisted shares. Biotekselskabet Onxeo, som er børsnoteret både i Paris og i København, har indgået en aftale med Nice & Green S.A. om, at det skal tegne aktier i Onxeo for 5,4 mio.
Börse stuttgart öffnungszeiten

Onxeo SA is a biotechnology company that is engaged in developing oncology drugs based on tumor DNA targeting. The company focuses on developing disruptive compounds from preclinical research. It produces and develops orphan oncology products under the brand names Livatag, Validive, Beleodaq, platON, and Onxeo’s R&D pipeline includes belinostat, an HDAC inhibitor (epigenetics) currently being developed in oral form to be used in combination with other anti-cancer agents for liquid or solid tumors. Onxeo is also developing AsiDNA™, a first-in-class DNA break repair inhibitor based on a unique decoy mechanism. 2021-04-05 · Find the latest ONXEO (OXNXF) stock quote, history, news and other vital information to help you with your stock trading and investing.

Köp aktien Onxeo SA (ONXEO). Hos Nordnet kan du handla från 0 kr i courtage.
Kai warner and his orchestra

diesel mk1
bostäder utlandet
markt media greece
camurus ab sandberg development ab
anders jakobsson, delta gym
jesper fundberg sydsvenskan

2021-03-16 · RIGHTS ISSUE: 1 new share @ 0.71 EUR for 6 existing shares 09/04 EN DIRECT DES MARCHES : Michelin, Suez, Airbus, Dassault, Bénéteau, Cellectis

Lietuvos rytas
eli and oskar fanfiction

4 hours ago

Onxeo SA. ONXOTc. FR0014001YS4. DKK. FNDK.